Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 421
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M1F0D75F932EN
Leaflet:

Download PDF Leaflet

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2016, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 10, 12, 72, 33 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 22 molecules, respectively.Methicillin-Resistant Staphylococcus aureus (MRSA) Infections.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Overview
Therapeutics Development
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Therapeutics under Development by Companies
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Therapeutics under Investigation by Universities/Institutes
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Products Glance
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Products under Development by Companies
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Products under Investigation by Universities/Institutes
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Companies Involved in Therapeutics Development
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Therapeutics Assessment
Drug Profiles
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Discontinued Products
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Product Development Milestones
Appendix 401

LIST OF TABLES

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2016
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Absynth Biologics Limited, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Actelion Ltd, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Adenium Biotech ApS, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AIMM Therapeutics B.V., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Alchemia Limited, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Allergan Plc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AlphaMab Co., Ltd, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Alvogen Korea Co., Ltd., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AmpliPhi Biosciences Corporation, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AnGes MG, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Antibiotx ApS, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Aphios Corporation, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Aridis Pharmaceuticals LLC, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Arsanis, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AstraZeneca Plc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Atriva Therapeutics GmbH, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Bavarian Nordic A/S, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Bharat Biotech International Limited, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by C3 Jian, Inc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Cellceutix Corporation, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Cempra Inc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Citius Pharmaceuticals, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Common Pharma Inc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by ContraFect Corporation, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Crestone, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Critical Outcome Technologies Inc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by CrystalGenomics, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by CSA Biotechnologies LLC , H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Debiopharm International SA , H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Dermala Inc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by DesignMedix, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Destiny Pharma Limited, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by e-Therapeutics Plc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Emergent BioSolutions Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Ensol Biosciences Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Excelimmune, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Galapagos NV, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by GangaGen Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Gero Corp, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Helix BioMedix, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Hsiri Therapeutics LLC, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Immupharma Plc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by iNtRON Biotechnology Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by ioGenetics, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lascco SA, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by LegoChem Biosciences, Inc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lipocure Ltd., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Madam Therapeutics B.V., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Melinta Therapeutics, Inc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Merck & Co., Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Microbiotix, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by MicuRx Pharmaceuticals, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by MorphoSys AG, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Motif Bio Plc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Nabriva Therapeutics AG, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Nemus Bioscience, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Novabiotics Limited, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by NovaDigm Therapeutics, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Omnia Molecular Ltd., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Oragenics, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Pfizer Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Phico Therapeutics Limited, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Procarta Biosystems Limited, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Prommune, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Recce Pty Ltd, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Redx Pharma Plc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sarepta Therapeutics, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Savara Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sealife PHARMA GMBH, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sentinella Pharmaceuticals, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sequoia Sciences Inc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Soligenix, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sorrento Therapeutics Inc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Taejoon Pharm Co., Ltd., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by TAXIS Pharmaceuticals, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Telephus Medical LLC, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by TGV-Laboratories, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Theravance Biopharma Inc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Trellis Bioscience, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Valevia UK Limited, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by VLP Biotech, Inc., H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Wintermute Biomedical LLC, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Wockhardt Limited, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by XBiotech Inc, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Yungjin Pharm. Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..1), H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..2), H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..3), H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..4), H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..5), H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..6), H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..7), H2 2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Discontinued Products, H2 2016 407

LIST OF FIGURES

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2016
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ask Your Question

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: